This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Middleton, M. K.
Right arrow Articles by Puré, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Middleton, M. K.
Right arrow Articles by Puré, E.

 Previous Article  |  Next Article 

Infection and Immunity, December 2009, p. 5690-5700, Vol. 77, No. 12
0019-9567/09/$08.00+0     doi:10.1128/IAI.00560-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

12/15-Lipoxygenase-Dependent Myeloid Production of Interleukin-12 Is Essential for Resistance to Chronic Toxoplasmosis {triangledown}

Melissa K. Middleton,1,2 Alicia M. Zukas,1 Tanya Rubinstein,1 Michelle Kinder,1,2 Emma H. Wilson,3 Peijuan Zhu,4 Ian A. Blair,4 Christopher A. Hunter,2,3 and Ellen Puré1,2,5*

The Wistar Institute,1 Immunology Graduate Group,2 School of Veterinary Medicine,3 Center for Cancer Pharmacology and Institute for Translational Medicine and Therapeutics,4 The Ludwig Institute for Cancer Research, University of Pennsylvania, Philadelphia, Pennsylvania 191045

Received 20 May 2009/ Returned for modification 23 June 2009/ Accepted 29 September 2009

Interleukin-12 (IL-12) is critical for resistance to Toxoplasma gondii during both the acute and chronic stages of infection. However, the cellular and molecular pathways that regulate IL-12 production during chronic toxoplasmosis are incompletely defined. We recently discovered that 12/15-lipoxygenase (12/15-LOX), which oxidizes unsaturated lipids in macrophages, is a novel and selective regulator of IL-12 production. We now demonstrate the essential role of this enzyme in the chronic phase of toxoplasmosis. Although 12/15-LOX-deficient mice were resistant to acute T. gondii infection, 80% of 12/15-LOX-deficient mice died during chronic toxoplasmosis, compared to no deaths in wild-type controls. The morbidity of chronically infected 12/15-LOX mice was associated with an increase in brain inflammation and parasite burden. These data suggest that the evolution of the immune response to T. gondii is accompanied by an increasing requirement for 12/15-LOX-mediated signaling. Consistent with this conclusion, 12/15-LOX activity was enhanced during chronic, but not acute, toxoplasmosis. Furthermore, the enhanced susceptibility of 12/15-LOX-deficient mice to chronic toxoplasmosis was associated with reduced production of IL-12 and gamma interferon (IFN-{gamma}) that was not evident during acute infection. Importantly, ex vivo IFN-{gamma} production by 12/15-LOX-deficient splenocytes could be rescued by the addition of recombinant IL-12. These data establish that 12/15-LOX is a critical mediator of the chronic type 1 inflammatory response and that immune mediators can be subject to distinct cellular and/or molecular mechanisms of regulation at different stages of inflammation.

* Corresponding author. Mailing address: The Wistar Institute, 3601 Spruce St., Rm. 368-372A, Philadelphia, PA 19104. Phone: (215) 898-1570. Fax: (215) 898-3937. E-mail: pure{at}wistar.org

{triangledown} Published ahead of print on 12 October 2009.

Editor: W. A. Petri, Jr.

Infection and Immunity, December 2009, p. 5690-5700, Vol. 77, No. 12
0019-9567/09/$08.00+0     doi:10.1128/IAI.00560-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»